Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

pantoprazole

- PMLiVE

Pfizer acquires option to license potential Parkinson’s treatment

Medgenesis cuts exclusive deal for its GDNF treatment

- PMLiVE

Questions raised about affordability of asthma antibodies

Positive data on GSK and Teva anti-IL-5 candidates at ERS congress highlights cost concerns

- PMLiVE

Teva supports launch of MS help website

Pow Health aims to help patients in Ireland with long term illnesses

- PMLiVE

Teva stakes its claim to the asthma antibody market

Plans to file reslizumab early next year

- PMLiVE

Rapid review for Pfizer’s superbug vaccine

FDA to expedite assessment of Clostridium difficile inoculation

- PMLiVE

Pfizer and Merck expand anti-PD1 cancer alliance

Will investigate combination of pembrolizumab and Xalkori

- PMLiVE

ViiV bags US approval for HIV blockbuster-in-waiting

Drug combines antiretrovirals with Tivicay

- PMLiVE

US panel backs pneumococcal vaccines for seniors

Vaccines to be provided by Merck & Co and Pfizer

- PMLiVE

Pfizer to work with genetics firm on bowel disease

Agrees deal with 23andMe to research ulcerative colitis and Crohn’s disease

EU flag

International regulators collaborate on generics

EMA leads three-year pilot project to increase pre-market data sharing

- PMLiVE

Pfizer closes on $1bn label expansion for Prevenar

EMA begins review of the pneumococcal vaccine

- PMLiVE

Pfizer’s arthritis drug Enbrel widens its European licence

Gains new indication for early-stage inflammatory joint disease

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links